AIM: To evaluate the efficacy of subconjunctival bevacizumab injection versus conjunctival autograft in management of recurrent pterygium. METHODS : 64 eyes of 64 patients affected with recurrent pterygium underwent surgical excision with bare sclera in the study group followed by subconjunctival bevacizumab while the control group was followed by conjunctival autograft . 32 eyes received subconjunctival bevacizumab injections, at the dosage of 1.25mg/0.5 ml. Recurrence rate was evaluated among the two groups. RESULTS: Mean age of patients in the study group was 39.62yrs while it was 41.5yrs in the control group. Post operative complications & recurrence were more in the control group. 12.5 % of patients had recurrence within 6months in the study group whereas there was 37.5 % recurrence in the control group. CONCLUSION: This study showed that subconjunctival injection of bevacizumab has better results in treatment of patients with recurrent pterygium without local or systemic adverse effects. At the present time we still await widespread standardization on the modality of administration, timing, and dosage of bevacizumab .